Literature DB >> 15152283

Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy.

Shane M Devlin1, Mark G Swain, Stefan J Urbanski, Kelly W Burak.   

Abstract

There are limited therapeutic options available for patients with autoimmune hepatitis in whom conventional treatment fails. A case series of five patients unresponsive to or unable to take azathioprine, 6-mercaptopurine or corticosteroids who were treated with mycophenolate mofetil (MMF) is reported. While on MMF, alanine aminotransferase normalized or remained normal in all patients. MMF had a steroid-sparing effect and histological remission was demonstrated in one patient after seven months of MMF. One patient experienced an uncomplicated episode of pyelonephritis. In conclusion, MMF can effectively induce and maintain remission in refractory autoimmune hepatitis patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15152283     DOI: 10.1155/2004/504591

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  26 in total

1.  Current status of therapy in autoimmune liver disease.

Authors:  Gideon M Hirschfield; Nadya Al-Harthi; E Jenny Heathcote
Journal:  Therap Adv Gastroenterol       Date:  2009-01       Impact factor: 4.409

2.  Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy.

Authors:  Kaveh Sharzehi; Mary Ann Huang; Ian R Schreibman; Kimberly A Brown
Journal:  Can J Gastroenterol       Date:  2010-10       Impact factor: 3.522

3.  Role of mycophenolate mofetil for the treatment of autoimmune hepatitis-an observational study.

Authors:  Dinesh Jothimani; Mathew E Cramp; Tim J S Cross
Journal:  J Clin Exp Hepatol       Date:  2014-06-24

Review 4.  Difficult treatment decisions in autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  World J Gastroenterol       Date:  2010-02-28       Impact factor: 5.742

5.  Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy.

Authors:  Kelly W Burak; Mark G Swain; Tania Santodomingo-Garzon; Tania Santodomino-Garzon; Samuel S Lee; Stefan J Urbanski; Alexander I Aspinall; Carla S Coffin; Robert P Myers
Journal:  Can J Gastroenterol       Date:  2013       Impact factor: 3.522

6.  Management of patients with difficult autoimmune hepatitis.

Authors:  Richard Parker; Ye Htun Oo; David H Adams
Journal:  Therap Adv Gastroenterol       Date:  2012-11       Impact factor: 4.409

7.  Mycophenolate mofetil for autoimmune hepatitis: a single practice experience.

Authors:  David C Wolf; Lizza Bojito; Marcelo Facciuto; Edward Lebovics
Journal:  Dig Dis Sci       Date:  2008-12-12       Impact factor: 3.199

Review 8.  Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment.

Authors:  Albert J Czaja; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2009-05-21       Impact factor: 5.742

9.  Mycophenolate mofetil for drug-induced vanishing bile duct syndrome.

Authors:  S-Simona Jakab; A-Brian West; Dennis-M Meighan; Robert S Brown; William-B Hale
Journal:  World J Gastroenterol       Date:  2007-12-07       Impact factor: 5.742

Review 10.  Update on autoimmune hepatitis.

Authors:  Andreas Teufel; Peter R Galle; Stephan Kanzler
Journal:  World J Gastroenterol       Date:  2009-03-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.